Artiva BiotherapeuticsARTV
13F holders, Q2 2025 (June 30)At the end of Q2 2025, 48 institutions reported holding Artiva Biotherapeutics Inc. (ARTV) in their 13F filings, down 5 from Q1 2025. 12 opened new positions and 17 sold out. The largest holders were Ra Capital Management, L.P. ($14.9M), 5AM Venture Management, LLC ($3.6M) and Venrock Adviser, LLC ($2.4M). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Artiva Biotherapeutics Inc.
- CUSIP
- 04317A107
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 12 | $1.1M |
| Exits | 17 | $3.7M |
All 13F filers, Q1 2025 → Q2 2025: 866,977 shares bought and 3,279,102 shares sold, net −2,412,125 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 48 holders
| Ra Capital Management, L.P. | 0.25% | No change | 9,853,302 | $14.9M |
| 5AM Venture Management, LLC | 1.37% | No change | 2,353,304 | $3.6M |
| Venrock Adviser, LLC | 0.18% | No change | 1,609,569 | $2.4M |
| venBio Partners LLC | 1.51% | Reduce -4.2% | 1,148,975 | $1.7M |
| Franklin Resources Inc. | 0.00% | No change | 520,327 | $786K |
| BlackRock, Inc. | 0.00% | Reduce -61.0% | 485,727 | $733K |
| Millennium Management | 0.00% | New | 327,067 | $494K |
| Samsara Biocapital, LLC | 0.09% | No change | 291,666 | $440K |
| Woodline Partners LP | 0.00% | No change | 283,124 | $428K |
| Vanguard Group Inc. | 0.00% | Reduce -72.8% | 232,972 | $352K |
| Wellington Management Group LLP | 0.00% | No change | 194,108 | $293K |
| Geode Capital Management, LLC | 0.00% | Reduce -61.3% | 159,041 | $240K |
| Citadel Advisors | 0.00% | Add +6.0% | 153,739 | $232K |
| Goldman Sachs Group Inc. | 0.00% | Add +181.3% | 118,003 | $178K |
| Alyeska Investment Group, L.P. | 0.00% | No change | 100,000 | $151K |
| HRT Financial LP | 0.00% | New | 77,656 | $117K |
| State Street Corp. | 0.00% | Reduce -63.4% | 62,874 | $95K |
| Marshall Wace, LLP | 0.00% | New | 52,213 | $79K |
| Morgan Stanley | 0.00% | Add +66.2% | 46,247 | $70K |
| Acuta Capital Partners, LLC | 0.10% | No change | 45,456 | $69K |
| Jane Street Group, LLC | 0.00% | New | 44,215 | $67K |
| FMR LLC | 0.00% | Add +1089.2% | 42,277 | $64K |
| Squarepoint Ops LLC | 0.00% | New | 41,395 | $63K |
| Qube Research & Technologies Ltd | 0.00% | New | 38,692 | $58K |
| Bridgeway Capital Management, LLC | 0.00% | New | 35,000 | $53K |
| Northern Trust Corp. | 0.00% | Reduce -75.3% | 34,964 | $53K |
| Y-Intercept (Hong Kong) Ltd | 0.00% | New | 31,567 | $48K |
| Ground Swell Capital, LLC | 0.06% | New | 24,849 | $38K |
| Two Sigma Investments, LP | 0.00% | New | 21,371 | $32K |
| Jain Global LLC | 0.00% | New | 17,171 | $26K |
| Susquehanna International Group, LLP | 0.00% | Reduce -33.8% | 16,121 | $24K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +286.3% | 10,098 | $15K |
| Russell Investments Group, Ltd. | 0.00% | New | 5,491 | $8K |
| Bank of America Corp. | 0.00% | Reduce -40.3% | 4,955 | $7K |
| China Universal Asset Management Co., Ltd. | 0.00% | Add +0.4% | 4,893 | $7K |
| Citigroup Inc. | 0.00% | Reduce -75.1% | 3,567 | $5K |
| Deutsche Bank AG | 0.00% | Reduce -84.2% | 3,383 | $5K |
| UBS Group AG | 0.00% | Reduce -92.3% | 3,337 | $5K |
| Wells Fargo & Company | 0.00% | Reduce -83.7% | 2,064 | $3K |
| Barclays PLC | 0.00% | Reduce -91.6% | 1,906 | $3K |
| Royal Bank of Canada | 0.00% | Add +134.3% | 1,120 | $2K |
| Mirae Asset Global Investments Co., Ltd. | 0.00% | Add +15.7% | 941 | $1K |
| JPMorgan Chase & Co. | 0.00% | Reduce -95.2% | 865 | $1K |
| BNP Paribas Financial Markets | 0.00% | Reduce -93.8% | 814 | $1K |
| GF Fund Management Co. LTD. | 0.00% | No change | 603 | $911 |
| Mark Sheptoff Financial Planning, LLC | 0.00% | No change | 400 | $604 |
| Nisa Investment Advisors, LLC | 0.00% | Add +100.6% | 329 | $497 |
| Cwm, LLC | 0.00% | Reduce -94.6% | 10 | $0 |
"% of holder's portfolio" is ARTV's weight in each manager's 13F, not the share of Artiva Biotherapeutics Inc. the manager owns.